At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 120 enrolled
Drug / intervention
Ginkgo biloba +1 moredrug
Likely dose
Ginkgo biloba 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ginkgo Biloba for Cognitive Impairment in Multiple Sclerosis
In Brief
A Phase 2 clinical trial evaluating Ginkgo biloba and Placebo for Multiple Sclerosis and Cognitive Ability, General. Completed, enrolled 120 participants across 2 sites.
Detailed Summary
The purpose of this study is to see if treatment with Ginkgo improves cognitive function in people with multiple sclerosis who have cognitive problems.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Cognitive Ability, General
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedFeb 2009
Primary CompletionNov 2010
Study CompletionDec 2010
TodayJul 2026
First PostedFeb 11, 2009
Enrollment StartJan 1, 2009
Primary CompletionNov 1, 2010
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.4 years ago
Interventions
Ginkgo bilobadrug
120 mg orally twice a day for 12 weeks
Placebodrug
One capsule orally twice a day for 12 weeks